Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 8/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 4/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25216893 | 0.84 | QRFPR (0.48) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL30301571 | 0.84 | QRFPR (0.48) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL30301590 | 0.83 | HSP90AA1 (0.54) | ACACBMCHR1HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL30368441 | 0.81 | QRFPR (0.42) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL25214972 | 0.81 | QRFPR (0.42) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL25224124 | 0.80 | QRFPR (0.44) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL30301552 | 0.80 | QRFPR (0.44) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL25205369 | 0.80 | HSP90AA1 (0.44) | ACACBF10MCHR1HSP90AA1HSP90AB1 | |
| SCHEMBL30462406 | 0.80 | HSP90AA1 (0.44) | ACACBF10MCHR1HSP90AA1HSP90AB1 | |
| SCHEMBL31281713 | 0.79 | PARP15 (0.36) | F10ENPP2HSP90AA1HSP90AB1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | claimed |
| CN-115996907-A | Inhibitors of MLH1 and/or PMS2 for cancer treatment | 奈奥芬莱有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4157463-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-04-05 | — | — | EP | claimed |
| CN-115996907-A | Inhibitors of MLH1 and/or PMS2 for cancer treatment | 奈奥芬莱有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4157463-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | QRFPR 3732/4885KCNH2 1582/4885CYP2D6 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.